Loading
EPHB1 (Ephrin type-B receptor 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.
Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Cognate/functional ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3.
Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.93, animal model 0.47, genetic association 0.35, clinical 0.93).
In plain words · EPHB1 (Ephrin type-B receptor 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.
EPHB1 (Ephrin type-B receptor 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.
Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells.
No product in this corpus aims at EPHB1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA EPHB1: RNA tissue enhanced (brain 19 nTPM); blood lineage group enriched (dendritic cells 23 nTPM, granulocytes 10 nTPM); high antibody staining in 1 normal tissue. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Thyroid cancer, Neuroendocrine tumours); Open Targets associates it with 1 specific cancer type at or above 0.5 (medullary thyroid gland carcinoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas EPHB1 tissue; Open Targets ENSG00000154928 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Tang X.X. et al, Genomics, 1995, "cDNA cloning, molecular characterization, and chromosomal localization of NET(EPHT2), a human EPH-related receptor protein-tyrosine kinase gene preferentially expressed in brain". Source.
Sources: HGNC HGNC:3392 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P54762 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000154928 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: thyroid cancer 0.56, neuroendocrine neoplasm 0.54 (GraphQL API, CC0))
Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Cognate/functional ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3. During nervous system development, regulates retinal axon guidance redirecting ipsilaterally ventrotemporal retinal ganglion cells axons at the optic chiasm midline. This probably requires repulsive interaction with EFNB2. In the adult nervous system together with EFNB3, regulates chemotaxis, proliferation and polarity of the hippocampus neural progenitors. Location: Cell membrane; Early endosome membrane; Cell projection, dendrite (UniProt). Locus 3q22.2 (HGNC).
RNA: tissue enhanced (brain 19 nTPM), detected in many normal tissues. Blood: group enriched (dendritic cells 23 nTPM, granulocytes 10 nTPM).
Medium: Bronchus, Cerebellum, Fallopian tube, Nasopharynx.
RNA cancer enriched: Glioblastoma Multiforme 19 pTPM.
No cancer stained high; medium in ovarian cancer, renal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"EPHB1" OR ABSTRACT:"EPHB1" OR TITLE:"EPH receptor B1" OR ABSTRACT:"EPH receptor B1" OR TITLE:"Ephrin type-B receptor 1" OR ABSTRACT:"Ephrin type-B receptor 1" OR TITLE:"Hek6" OR ABSTRACT:"Hek6" OR TITLE:"EPHT2" OR ABSTRACT:"EPHT2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EPHB1, not a curated reading list.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Open Targets Platform.